We further extend this hypothesis to suggest that in AMD, locally delivered ACA at an earlier disease stage will block the local generation of C3a and C5a around the RPE/photoreceptor interface, stop RPE atrophy and also stop muller glia activation55. Here, C5 is linked to age-related macular degeneration.